Background. Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling and vasoconstriction, leading to increased pulmonary vascular resistance and right-side heart failure. In recent years PAH specific oral therapies have become available. Bosentan and sildenafil are effective therapies for PAH. However, it is a common clinical experience that some patients have clinical worsening (CW) during long-term oral treatment. Objectives. The aim of the study was to describe the efficacy of additional therapy with subcutaneous or intravenous prostanoids in PAH patients deteriorating on bosentan or sildenafil.
EFFICACY OF PROSTANOID THERAPY IN PULMONARY ARTERIAL HYPERTENSION PATIENTS WITH CLINICAL WORSENING ON ORAL THERAPY / Roberto, Poscia; Vizza, Carmine Dario; Badagliacca, Roberto; Sciomer, Susanna; Cristina, Gambardella; Pezzuto, Beatrice; Silvia, Papa; Mancone, Massimo; Ferrante, Fabio; Fedele, Francesco. - In: SUPPLEMENTI ALL'ITALIAN HEART JOURNAL. - ISSN 1590-3796. - STAMPA. - 10 suppl. 1:(2009), pp. 125-125.
EFFICACY OF PROSTANOID THERAPY IN PULMONARY ARTERIAL HYPERTENSION PATIENTS WITH CLINICAL WORSENING ON ORAL THERAPY
VIZZA, Carmine Dario;BADAGLIACCA, ROBERTO;SCIOMER, Susanna;BEATRICE PEZZUTO;SILVIA PAPA;MANCONE, Massimo;FERRANTE, Fabio;FEDELE, Francesco
2009
Abstract
Background. Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling and vasoconstriction, leading to increased pulmonary vascular resistance and right-side heart failure. In recent years PAH specific oral therapies have become available. Bosentan and sildenafil are effective therapies for PAH. However, it is a common clinical experience that some patients have clinical worsening (CW) during long-term oral treatment. Objectives. The aim of the study was to describe the efficacy of additional therapy with subcutaneous or intravenous prostanoids in PAH patients deteriorating on bosentan or sildenafil.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
